Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Purpose Triple-negative breast cancer (TNBC) accounts for approximately 20% of breast cancer cases. Although there have been advances in the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancers, targeted therapies for TNBC remain unavailable. In this narrative review, we summarize recent discoveries related to the underlying biology of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway in TNBC, examine clinical progress to date, and suggest rational future approaches for investigational therapies in TNBC.Results As with other subtypes of breast cancer, aberrations in the PI3K/AKT/mTOR pathway are common in TNBC. Preclinical data support the notion that these aberrations predict TNBC inhibition by targeted agents. In a recently published phase 2 clinical trial, an AKT inhibitor (ipatasertib) improved outcomes in a subset of patients with metastatic TNBC when combined with paclitaxel in the first-line setting. In addition, new compounds with distinct specificity and potency targeting different PI3K/AKT/mTOR components and cognate molecules (e.g., mitogen-activated protein kinase) are being developed. These agents present a wide range of toxicity profiles and early efficacy signals, which must be considered prior to the advancement of new agents in later-phase clinical trials.Conclusions The development of drugs targeting the PI3K/AKT/mTOR pathway for the treatment of TNBC is an evolving field that should take into account the efficacies and toxicities of new agents in addition to their interactions with different cancer pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These targeted genes and pathways are essential for the proliferation, migration, and invasion of TNBC cells47,48, and were suggested as therapeutic drug targets for TNBC in previous studies49,50.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [47]
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
Lannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M. M., Deininger, M., et al. (2011) · Blood · doi:10.1182/blood-2010-03-275305 · Cited by 720
Guarneri, V., Broglio, K., Kau, S.-W., Cristofanilli, M., Buzdar, A. U., Valero, V., Buchholz, T., Meric, F., Middleton, L., Hortobagyi, G. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6914 · Cited by 601
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Baselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 470
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Knight, S. D., Adams, N. D., Burgess, J. L., Chaudhari, A. M., Darcy, M. G., Donatelli, C. A., Luengo, J. I., Newlander, K. A., Parrish, C. A., Ridgers, L. H., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900028r · Cited by 373
Chakrabarty, A., Sánchez, V., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347
Mayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D., Berger, M. F., Won, H. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0134 · Cited by 319
Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 313
Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M., Johnston, S., Morales, S., Yardley, D. A., Melichar, B., Forero-Torres, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295
Lin, J., Sampath, D., Nannini, M. A., Lee, B. B., Degtyarev, M., Oeh, J., Savage, H., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 294
Burger, M. T., Pecchi, S., Wagman, A., Ni, Z.-J., Knapp, M., Hendrickson, T., Atallah, G., Pfister, K., Zhang, Y., Bartulis, S., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200156t · Cited by 252
Addie, M., Ballard, P., Buttar, D., Crafter, C., Currie, G., Davies, B. R., Debreczeni, J., Dry, H., Dudley, P., Greenwood, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301762v · Cited by 230
Wallin, J. J., Edgar, K. A., Guan, J., Berry, M., Prior, W. W., Lee, L., Lesnick, J. D., Lewis, C., Nonomiya, J., Pang, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0446 · Cited by 229
Beger, C., Pierce, L. N., Krüger, M., Marcusson, E. G., Robbins, J. M., Welcsh, P., Welch, P. J., Welte, K., King, M.-C., Barber, J. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.130 · Cited by 221
Craig, D. W., O'Shaughnessy, J. A., Kiefer, J. A., Aldrich, J., Sinari, S., Moses, T. M., Wong, S., Dinh, J., Christoforides, A., Blum, J. L., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0781 · Cited by 220
Sutherlin, D. P., Bao, L., Berry, M., Castanedo, G., Chuckowree, I., Dotson, J., Folks, A., Friedman, L., Goldsmith, R., Gunzner, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2009327 · Cited by 219
Keller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J.-M., Erazo, A., Lluch, A., Vogel, C. L., Kaufmann, M., von Minckwitz, G., Henderson, I. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.157 · Cited by 214
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
Champiat, S., Ferté, C., Lebel-Binay, S., Eggermont, A., & Soria, J. C. (2014) · OncoImmunology · doi:10.4161/onci.27817 · Cited by 192
Basho, R. K., Gilcrease, M., Murthy, R. K., Helgason, T., Karp, D. D., Meric-Bernstam, F., Hess, K. R., Herbrich, S. M., Valero, V., Albarracin, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5281 · Cited by 188
Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquiere, N., Bradley, E., Bull, R., Do, S., Dotson, J., Dudley, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 179
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Mallon, R., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E. D., Chen, Z., dos Santos, O., Ayral-Kaloustian, S., Venkatesan, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1694 · Cited by 172
Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair
Kumar, A., Fernandez-Capetillo, O., & Carrera, A. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914242107 · Cited by 165
Prenzel, N., Zwick, E., Leserer, M., & Ullrich, A. (2000) · Breast Cancer Research · doi:10.1186/bcr52 · Cited by 149
Chemical modification of rapamycin: the discovery of SDZ RAD
Sedrani, R. C., Cottens, S., Kallen, J. A., & Schüler, W. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)00587-9 · Cited by 147
Shapiro, G. I., Bell‐McGuinn, K. M., Molina, J. R., Bendell, J. C., Spicer, J. F., Kwak, E. L., Pandya, S. S., Millham, R., Borzillo, G. V., Pierce, K. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1306 · Cited by 137
Diaz, L. K., Cryns, V. L., Symmans, W. F., & Sneige, N. (2007) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181594733 · Cited by 132
Shor, B., Zhang, W., Toral‐Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., & Yu, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6487 · Cited by 131
Baldassarre, G., Battista, S., Belletti, B., Thakur, S., Pentimalli, F., Trapasso, F., Fedele, M., Pierantoni, G. M., Croce, C. M., & Fusco, A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.7.2225-2238.2003 · Cited by 128
Ooms, L. M., Binge, L. C., Davies, E. M., Rahman, P., Conway, J. R. W., Gurung, R., Ferguson, D. T., Papa, A., Fedele, C. G., Vieusseux, J. L., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.003 · Cited by 127
del Campo, J. M., Birrer, M. J., Davis, C. B., Fujiwara, K., Gollerkeri, A. M., Gore, M. E., Houk, B. E., Lau, S. K., Poveda, A. M., González-Martín, A., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.019 · Cited by 122
De, P. K., Sun, Y., Carlson, J. H., Friedman, L. S., Leyland-Jones, B. R., & Dey, N. (2014) · Neoplasia · doi:10.1593/neo.131694 · Cited by 118
Dirix, L. Y., Takács, I., Nikolinakos, P. G., Jérusalem, G., Arkenau, H., Hamilton, E. P., von Heydebreck, A., Grote, H.-J., Chin, K. M., & Lippman, M. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s1-04 · Cited by 112
Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells
Liu, T., Yacoub, R., Taliaferro-Smith, L. D., Sun, S., Graham, T. R., Dolan, R. S., Lobo, C., Tighiouart, M., Yang, L. P. H., Adams, A. L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0925 · Cited by 109
Juric, D., Bono, J. S. D., LoRusso, P. M., Nemunaitis, J. J., Heath, E. I., Kwak, E. L., Macarulla, T. M., Geuna, E., Miguel, M. J. D., Patel, C. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2888 · Cited by 107
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
Cossu‐Rocca, P., Orrù, S., Muroni, M. R., Sanges, F., Sotgiu, G., Ena, S., Pira, G., Murgia, L., Manca, A., Uras, M. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141763 · Cited by 104
Barlaam, B. C., Cosulich, S. C., Degorce, S. L., Fitzek, M., Green, S. A., Hancox, U. J., der Brempt, C. L., Lohmann, J.-J. M., Maudet, M., Morgentin, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501629p · Cited by 95
A Phase 2 study of perifosine in advanced or metastatic breast cancer
Leighl, N. B., Dent, S. F., Clemons, M. J., Vandenberg, T. A., Tozer, R. G., Warr, D. G., Crump, R. M., Hedley, D. W., Pond, G. R., Dancey, J. E., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9584-x · Cited by 91
Gökmen‐Polar, Y., Liu, Y., Toroni, R. A., Sanders, K. L., Mehta, R. J., Badve, S., Rommel, C., & Sledge, G. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2298-8 · Cited by 85
Liu, H., Murphy, C. J., Karreth, F. A., Emdal, K. B., White, F. M., Elemento, O., Toker, A., Wulf, G. M., & Cantley, L. C. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0679 · Cited by 79
Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I., Veeriah, S., Deng, G. Y., Coram, M., Piskun, C. M., Longacre, T. A., Herrler, M., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3640 · Cited by 78
mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors
Walsh, S., Flanagan, L., Quinn, C., Evoy, D., McDermott, E. W. M., Pierce, A., & Duffy, M. J. (2011) · The Breast · doi:10.1016/j.breast.2011.09.008 · Cited by 74
Ueng, S., Chen, S., Chang, Y., Hsueh, S., Lin, Y., Chien, H., Lo, Y.-F., Shen, S., & Hsueh, C. (2012) · Europe PMC (PubMed Central) · Cited by 70
Kriegsmann, M., Endris, V., Wolf, T. A., Pfarr, N., Stenzinger, A., Loibl, S., Denkert, C., Schneeweiß, A., Budczies, J., Sinn, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2481 · Cited by 69
Tolaney, S. M., Burris, H. A., Gartner, E. M., Mayer, I. A., Saura, C., Maurer, M., Ciruelos, E., García, A. A., Campana, F., Wu, B., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3248-4 · Cited by 59
Wisinski, K. B., Tevaarwerk, A. J., Burkard, M. E., Rampurwala, M. M., Eickhoff, J. C., Bell, M. C., Kolesar, J., Flynn, C. M., & Liu, G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2365 · Cited by 54
Xu, S., Li, S., Guo, Z., Luo, J. R., Ellis, M. J., & Ma, C. X. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0159 · Cited by 47
Rugo, H. S., Roche, H. H., Thomas, E., Blackwell, K., Chung, H., Lerzo, G. L., Volles, L., Poulart, V., & Perez, E. A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-3057 · Cited by 46
Tzeng, H.-E., Yang, L., Chen, K., Wang, Y., Liu, Y., Pan, S., Gaur, S., Hu, S., & Yen, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3568 · Cited by 44
Hatem, R., Botty, R. E., Château‐Joubert, S., Servely, J., Labiod, D., de Plater, L., Assayag, F., Coussy, F., Callens, C., Vacher, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10195 · Cited by 41
Characterization of a Chemical Affinity Probe Targeting Akt Kinases
Pachl, F., Plattner, P., Ruprecht, B., Médard, G., Sewald, N., & Küster, B. (2013) · Journal of Proteome Research · doi:10.1021/pr400455j · Cited by 36
Hoeflich, K. P., Guan, J., Edgar, K. A., O'Brien, C. L., Savage, H. M., Wilson, T. R., Neve, R. M., Friedman, L. S., & Wallin, J. J. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.100 · Cited by 19
Peek, G. W., & Tollefsbol, T. O. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25462 · Cited by 11
Schmid, P., Wheatley, D. A., Baird, R. D., Chan, S. Y. T., Abraham, J., Tutt, A. N. J., Kristeleit, H., Patel, G. S., Bathakur, U., Bishop, J., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-ot1-03-13 · Cited by 4
Yuan, Y., Mortimer, J. E., Xing, Q., Yan, J., Wen, W. X., Han, E. S., & Yim, J. (2017) · Cancer Research · doi:10.1158/1538-7445.sabcs16-p3-03-15 · Cited by 3
Cited by
Akt in cancer: Mediator and more
Revathidevi, S., & Munirajan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.002 · Cited by 691
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 375
“The combination of endocrine therapy with most PI3K inhibitors, such as buparlisib in the BELLE-2 study and the PI3Kα inhibitors alpelisib and taselisib in the SOLAR-1 and SANDPIPER studies, respectively, has demonstrated potent anticancer effects in HR+/HER2− and AI-resistant breast cancer (Baselga et al., 2017; Base…”
BackgroundFrequency and spectrum of PIK3CA somatic mutations in breast cancer
Martínez-Sáez, O., Chic, N., Pascual, T., Adamo, B., Vidal, M., González-Farré, B., Sanfeliu, E., Schettini, F., Conte, B., Brasó-Maristany, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01284-9 · Cited by 380
“In addition, several trials are now evaluating alpelisib and other alphaspecific PI3K inhibitors in other BC subtypes harboring PIK3CA mutations [27].”
BackgroundGupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Metadata
- Authors
- Costa, R. L. B., Han, H. S., & Gradishar, W. J.
- Affiliations
- Moffitt Cancer Center (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University (US)
- Corresponding author
- Costa, Ricardo L. B.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2018-02-07
- Volume
- 169
- Issue
- 3
- Pages
- 397-406
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2786784128
- Cited by
- 439
- References
- 73
- Citations by year
- 2026: 19 · 2025: 38 · 2024: 37 · 2023: 77 · 2022: 65 · 2021: 67 · 2020: 68 · 2019: 47 · 2018: 20
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- triple-negative breast cancer, PI3K/AKT/mTOR pathway, targeted therapy, ipatasertib, AKT inhibitors, mTOR inhibitors, PI3K inhibitors, MAPK inhibitors, paclitaxel, metastatic breast cancer, drug toxicity, drug interactions
- MeSH terms
- Animals, Female, Humans, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.